

ImpediMed Limited
1/50 Parker Court,
Pinkenba, QLD, 4008
Australia

E: investorrelations@impedimed.com

W: impedimed.com

24 September 2024

Companies Announcements Office
Australian Securities Exchange

Positive coverage published by two additional payors

ImpediMed Limited (ASX: IPD) is pleased to announce Emblem Health (NY, CT and NJ) and Presbyterian Health (NM) have updated their medical policies to include positive coverage for the use of Bioimpedance Spectroscopy (BIS) for lymphedema assessment.

Key Points

- Total covered lives increased to 144 million
- 16 states now at Critical Mass (>80% covered lives)
- 18 private payors providing positive coverage
- 39 private payors providing silent coverage

Emblem Health, covering lives in New York, Connecticut and New Jersey, has updated its policy to include BIS for lymphedema assessment for breast cancer patients with no pre-authorisation, resulting in ~88% payor coverage in New York (4th largest state by population with ~20 million). In addition, Presbyterian Health, the largest payor in New Mexico, has updated its policy to include BIS for lymphedema assessment with no pre-authorisation.

Commenting on the additional private payor coverage and the Company's commercial progress, ImpediMed Chief Executive Officer and Managing Director, Dr Bains, said, "we are pleased to see growing coverage, and the achievement of medically necessary status supports the ability of patients across the U.S. to access early lymphoedema screening."

Approved for release by: Dr Parmjot Bains, CEO/MD

For more information, contact Dr Parmjot Bains or McGregor Grant on +61 7 3860 3700.

For personal use only

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO[®] Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines[®]) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex[®], ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward Looking Statements

This announcement contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited).